- Home
- PML vs SIGA Comparison
PML vs SIGA Comparison
Compare PML & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PML
- SIGA
- Stock Information
- Founded
- PML 2002
- SIGA 1995
- Country
- PML United States
- SIGA United States
- Employees
- PML N/A
- SIGA N/A
- Industry
- PML Investment Managers
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- PML Finance
- SIGA Health Care
- Exchange
- PML Nasdaq
- SIGA Nasdaq
- Market Cap
- PML 576.5M
- SIGA 620.9M
- IPO Year
- PML N/A
- SIGA 1997
- Fundamental
- Price
- PML $9.35
- SIGA $6.98
- Analyst Decision
- PML
- SIGA
- Analyst Count
- PML 0
- SIGA 0
- Target Price
- PML N/A
- SIGA N/A
- AVG Volume (30 Days)
- PML 188.0K
- SIGA 664.0K
- Earning Date
- PML 01-01-0001
- SIGA 08-01-2024
- Dividend Yield
- PML 5.65%
- SIGA 8.60%
- EPS Growth
- PML N/A
- SIGA 197.35
- EPS
- PML N/A
- SIGA 1.17
- Revenue
- PML N/A
- SIGA $172,956,776.00
- Revenue This Year
- PML N/A
- SIGA $29.44
- Revenue Next Year
- PML N/A
- SIGA N/A
- P/E Ratio
- PML N/A
- SIGA $5.97
- Revenue Growth
- PML N/A
- SIGA 76.90
- 52 Week Low
- PML $6.92
- SIGA $4.26
- 52 Week High
- PML $9.46
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- PML 64.01
- SIGA 38.88
- Support Level
- PML $9.14
- SIGA $6.80
- Resistance Level
- PML $9.52
- SIGA $7.10
- Average True Range (ATR)
- PML 0.10
- SIGA 0.42
- MACD
- PML 0.01
- SIGA -0.04
- Stochastic Oscillator
- PML 65.74
- SIGA 16.51
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.